FLT3 and acute myeloid leukemia: In this global, randomized, placebo-controlled Phase III trial of 717 patients with FLT3-mutated AML, the addition of midostaurin to induction and consolidation chemotherapy, followed by 12-month midostaurin maintenance therapy, resulted in superior survival rates compared to chemotherapy alone [7.2% difference in 4-year overall survival (OS)].